Our product is the first screening kit in the market with a selection of evolved fungal unspecific peroxygenases (UPOs), designed to achieve scalable production of chemicals and human drug metabolites.
Coming from different fungal species (short and long-type UPO families), our exclusive collection of evolved UPOs can perform an extensive range of selective oxyfunctionalizations on pharmacological compounds, emulating the role of human liver P450 monoxygenases. Unlike P450s, UPOs simply use H2O2 as an oxidant, making laboratory manipulations easier and more robust.
The catalytic repertoire of the selected UPOs in EVOkit are relevant to both the pharmaceutical and chemical sector, and its portfolio includes alkyl and aromatic hydroxylations, aliphatic and aromatic epoxidations, O-dealkylations, N-dealkylations (including ester and ether cleavage), N-oxidations, S-oxidations and brominations.
EVOkit content
Our best mutants
Our fungal peroxygenase kit is presented in glass vials to carry out efficient and directed screening, following a step-by-step protocol. It contains 12 evolved UPO variants selected for their catalytic properties, encompassing a wide array of biotransformations and selectivity.
To make the assay easier, the EVOkit also contains three accessory vials with reaction buffer, hydrogen peroxide and a UPO substrate to use it as a positive control.
We also offer constant support to our customers to assist them with any specific reactions they wish to carry out with the EVOkit.
EVOkit case study
Synthesis of human drug metabolites
We have tested two engineered UPO variants in the EVOkit for their capacity to synthesise authentic human drug metabolites (HDMs). They do this from three pharmaceutical compounds of interest: dextromethorphan, naproxen and tolbutamide.